更新于：2024-05-01
Levodopa/Benserazide Hydrochloride
多巴丝肼
更新于：2024-05-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1973-06-27), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C19H26N4O9 |
InChIKeyQFLMOYQNYBDXMT-ZCMDIHMWSA-N |
CAS号37270-69-2 |
关联
53
项与 多巴丝肼 相关的临床试验多巴丝肼片随机、开放、交叉设计在中国健康受试者中的生物等效性正式试验
多巴丝肼片（0.25g）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
多巴丝肼片单中心、随机、开放、单次给药、两制剂、两序列、四周期、重复生物等效性试验
100 项与 多巴丝肼 相关的临床结果
登录后查看更多信息
100 项与 多巴丝肼 相关的转化医学
登录后查看更多信息
100 项与 多巴丝肼 相关的专利（医药）
登录后查看更多信息
464
项与 多巴丝肼 相关的文献（医药）2024-02-20Chemosphere
Adsorption of anti-inflammatory and analgesic drugs traces in water on clay minerals.
Article
作者: Fatma Mansouri ; Khawla Chouchene ; Ahmed Wali ; Jerome Labille ; Nicolas Roche ; Mohamed Ksibi
The aim of this study was to assess the adsorption of four non-steroidal anti-inflammatory drugs (NSAIDs), namely Paracetamol (PRC), Diclofenac (DIC), Ibuprofen (IBU), and Ketoprofen (KET), using both batch and continuous experiments with clay. Various analytical techniques, including XRD, FTIR, SEM coupled to EDX, and Zeta potential, were employed to characterize both raw and calcined clay. XRD and FTIR analyses confirmed the kaolinite nature of the clay. SEM data revealed a lamellar structure formed in the clay after calcination at 550 °C. Adsorption tests were conducted to determine the optimal adsorption conditions. Batch kinetics of adsorption demonstrated rapid adsorption of all four NSAIDs, with the highest adsorption occurring at pH 4 (DIC, IBU, and KET) and pH 6 for PRC, using a concentration of 20 mg L-1 of calcined clay. Additionally, the pseudo-second-order model provided the best fit for all NSAIDs adsorption processes. Maximum adsorption capacities, as determined by the Langmuir model, were 80 mg g-1 for PRC, 238 mg -1g for DIC, 138 mg g-1 for IBU, and 245 mg g-1 for KET. In fixed bed column studies, three dynamic models (Thomas, Adams-Bohart, and Yoon-Nelson) were utilized to describe the breakthrough curves, with linear regression used to identify key characteristics for process design. The fixed bed column adsorption study revealed that DIC exhibited the highest removal efficiency at 98%, while KET, IBU, and PRC were more persistent, with removal efficiencies of 77.1%, 76.7%, and 67.1%, respectively. The Thomas model was deemed appropriate for describing the breakthrough curve. These findings offer valuable insights into the interactions between clay and pharmaceuticals with varying physicochemical properties. They also provide information on the adsorption models, saturation, and adsorption capacities of various pharmaceuticals on natural clays, which can be crucial for further research and environmental remediation efforts.
2024-02-16Journal of controlled release : official journal of the Controlled Release Society
Rhamnose-PEG-induced supramolecular helices: Addressing challenges of drug solubility and release efficiency in transdermal patch.
Article
作者: Haoyuan Song ; Chao Liu ; Jiuheng Ruan ; Yu Cai ; Jiaqi Wang ; Xiaoxu Wang ; Liang Fang
Transdermal drug delivery systems (TDDS) demand both high drug loading capacity and efficient delivery. In order to improve both simultaneously, this study aims to develop a novel rhamnose-induced pressure-sensitive adhesive (HPR) by dispersing the drug in the supramolecular helical structure. Ten model drugs, categorized as acidic and basic compounds, were chosen to understand the characteristics of the HPR and its inner mechanism. Notably, it enhanced drug loading by 1.41 to 5 times over commercially available pressure-sensitive adhesives Duro-Tak@ 87-4098 and Duro-Tak@ 87-2287, in addition to increasing drug release efficiency by a factor of about 5. Pharmacokinetic evaluation demonstrated that the HPR group had >4-fold (Tulobuterol TUL) and 3-fold (Diclofenac DIC) more area under the blood drug concentration curve (AUC) than the commercial TUL and DIC patches in the absence of added excipients and a significantly prolonged mean residence time (MRT) of >4-fold (TUL) and 3-fold (DIC), demonstrating the potential for highly efficacious and prolonged dosing. Furthermore, its safety and mechanical properties meet the requisite standards. Mechanistic inquiries unveiled that both acidic and basic drugs establish hydrogen bonds with HPR and become encapsulated within supramolecular helical structures. The supramolecular helical structures, significantly elevated both the enthalpy of the drug-HPR and entropy of the drugs release, thereby substantially enhancing drug delivery efficiency. In summary, HPR enabled a significant simultaneous enhancement of drug loading and drug delivery, which, together with its unique spatial structure, would contribute to the development of TDDS. In addition, the establishment of rhamnose-induced supramolecular helical structures would provide innovative pathways for different drug delivery systems.
2023-12-10Cellular and molecular biology (Noisy-le-Grand, France)
Effect of Gushen shetuo decoction in improving motor and non-motor symptoms and the expression of PERK, ATF4 and CHOP in patients with Parkinson's disease.
Article
作者: Peishan Li ; Ning Yang ; Weifeng Guo ; Houxu Ning ; Wenhao Cheng ; Haidong Wang
This study aims to observe the therapeutic effect of Gushen Shetuo decoction on Parkinson's disease (PD), so as to provide reference for clinical practice. In order to demonstrate the clinical value of Gushen Shetuo Decoction, we selected 80 patients with PD for the study. Among them, 38 patients received the Gushen Shetuo decoction (research group), and 42 patients received Levodopa and Benserazide Hydrochloride Tablets (control group). There was no difference in Non-Motor Symptoms Scale (NMSS) scores between the research group and the control group (P>0. 05). However, the scores of motor complications in Movement Disorder Society-sponsored revision of the Parkinson's Disease Rating Scale (MDS-UPDRS) and those of Drooling Severity and Frequency Scale (DSFS) in the research group were lower than those in the control group (P<0. 05). Subsequently, we established PD model rats, and after Gushen Shetuo Decoction gavage treatment, we found that rats in the intervention group had increased mobility (P<0. 05), as well as notably improved pathological damage of substantia nigra and striatum. Also, the expression of PERK, ATF4 and CHOP in the brain tissues of rats in the intervention group was lower than those in the control group (P<0. 05). These results confirm that Gushen Shetuo decoction effectively improved the drooling of patients with PD and showed high safety.
100 项与 多巴丝肼 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 帕金森病 | 批准上市 | 日本 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 32 | (淵糧鑰廠鑰糧繭觸鏇窪) = In our study, there are only two patients having rashes 壓衊願鹽夢衊廠艱膚壓 (鬱艱鏇鑰窪窪艱選願繭 ) 更多 | 不佳 | 2017-06-04 | ||
临床2期 | 40 | (顧襯築鹽壓鹽選觸遞製) = 築壓顧積築築窪窪衊選 簾壓衊鏇網糧壓壓願餘 (願壓襯艱窪鏇糧夢顧觸, 衊簾鏇願觸鹽獵鏇遞鏇 ~ 選壓選餘憲廠鑰窪壓製) 更多 | - | 2015-01-08 | |||
临床1期 | 52 | (Placebo) | (鏇膚觸糧顧膚蓋網獵蓋) = 鏇獵憲製餘餘願艱窪遞 積齋繭膚網鹹鏇糧淵積 (鑰選簾築積鹽憲餘顧範, 衊窪獵鹽壓遞簾鑰蓋壓 ~ 膚遞醖製憲製獵鬱鑰醖) 更多 | - | 2015-11-16 | ||
(5 mg BIA 9-1067) | (鏇膚觸糧顧膚蓋網獵蓋) = 顧鹽壓構遞壓夢遞憲獵 積齋繭膚網鹹鏇糧淵積 (鑰選簾築積鹽憲餘顧範, 憲鏇齋築簾選顧膚積艱 ~ 窪觸廠餘簾廠觸糧繭衊) 更多 | ||||||
临床3期 | 427 | 積壓鏇積簾鬱壓願膚遞(襯構製廠鹹艱襯蓋積鑰) = 鹽築憲構願範顧觸膚觸 蓋夢鬱鹹簾齋醖糧糧膚 (襯憲鬱繭餘襯獵構鑰窪, 蓋衊築醖膚顧齋憲醖鬱 ~ 齋壓憲廠壓鹽顧鏇顧淵) 更多 | - | 2015-01-13 | |||
N/A | - | 餘願簾醖簾醖膚憲範網(觸醖餘鑰構齋網襯遞鬱) = 壓夢鑰觸襯範選廠獵艱 構蓋積淵夢願顧壓積窪 (蓋鏇蓋鹽廠夢餘齋鬱淵 ) | 不佳 | 2023-08-27 | |||
Placebo | 餘願簾醖簾醖膚憲範網(觸醖餘鑰構齋網襯遞鬱) = 鬱鏇廠鏇餘觸齋鹽遞壓 構蓋積淵夢願顧壓積窪 (蓋鏇蓋鹽廠夢餘齋鬱淵 ) | ||||||
临床3期 | 600 | (Placebo) | 觸鏇夢顧壓壓醖遞齋遞(簾淵簾蓋鹹醖築製鹽鹽) = 窪糧壓憲鹹簾選鑰觸積 壓艱遞窪齋餘夢鹽積獵 (鑰獵壓遞積壓襯淵憲壓, 鹽網選觸鏇鬱壓獵壓淵 ~ 鹹網鹹獵製鏇壓壓蓋構) 更多 | - | 2015-01-08 | ||
(Entacapone) | 觸鏇夢顧壓壓醖遞齋遞(簾淵簾蓋鹹醖築製鹽鹽) = 網鬱壓積鬱獵膚夢製壓 壓艱遞窪齋餘夢鹽積獵 (鑰獵壓遞積壓襯淵憲壓, 憲範糧餘醖壓網鹽醖憲 ~ 艱衊窪餘製鑰鬱鑰膚壓) 更多 | ||||||
临床4期 | - | 24 | (鹹壓壓積壓築醖艱構繭) = 繭構餘鹹蓋繭製鏇簾範 願齋糧觸製顧蓋窪衊窪 (鏇壓鑰窪鏇顧襯夢繭鑰, 3623.88 ~ 5393.09) 更多 | - | 2011-04-01 | ||
Reference formulation | (鹹壓壓積壓築醖艱構繭) = 壓壓鬱範獵觸製願淵醖 願齋糧觸製顧蓋窪衊窪 (鏇壓鑰窪鏇顧襯夢繭鑰, 3765.88 ~ 5393.02) 更多 | ||||||
临床3期 | - | 551 | 膚遞憲遞窪齋齋範觸顧(艱醖範醖襯夢蓋廠窪簾) = 淵糧製膚願繭鏇願窪選 蓋製構壓觸衊夢願齋願 (糧範廠鹹鬱壓積餘衊窪 ) 更多 | - | 2015-12-01 | ||
膚遞憲遞窪齋齋範觸顧(艱醖範醖襯夢蓋廠窪簾) = 餘鏇繭糧餘襯鏇鑰網網 蓋製構壓觸衊夢願齋願 (糧範廠鹹鬱壓積餘衊窪 ) 更多 | |||||||
临床1期 | 74 | (Placebo) | 觸艱醖憲範齋鏇蓋衊積(範顧願糧夢夢鏇網鹹顧) = 夢簾襯構積選壓鏇繭艱 蓋積蓋築繭築廠齋醖蓋 (鬱憲鑰夢壓夢夢願憲齋, 艱範積鬱淵願餘鹽餘簾 ~ 餘選製鑰蓋窪製網醖廠) 更多 | - | 2015-12-24 | ||
(BIA 9-1067 5 mg) | 觸艱醖憲範齋鏇蓋衊積(範顧願糧夢夢鏇網鹹顧) = 網觸顧蓋膚範襯廠餘淵 蓋積蓋築繭築廠齋醖蓋 (鬱憲鑰夢壓夢夢願憲齋, 鏇齋艱艱鏇襯築觸願顧 ~ 鏇淵獵壓齋積築選繭糧) 更多 | ||||||
N/A | - | 鹹淵獵願窪顧獵憲鑰餘(範艱獵築鏇窪範壓簾簾) = 餘構顧積網餘衊觸簾鏇 鑰齋齋壓憲窪繭艱憲衊 (壓鏇鹽鏇夢簾鹹鬱蓋遞 ) | 积极 | 2020-05-25 | |||
Dari | 鹹淵獵願窪顧獵憲鑰餘(範艱獵築鏇窪範壓簾簾) = 糧獵膚鏇鏇顧簾製衊遞 鑰齋齋壓憲窪繭艱憲衊 (壓鏇鹽鏇夢簾鹹鬱蓋遞 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用